Estimating the overall survival benefit of adjuvant chemo‐endocrine therapy in women over age 50 with pT1‐2N0 early stage breast cancer and 21‐gene recurrence score ≥26: A National Cancer Database analysis

BACKGROUND: Validation studies of the 21‐gene recurrence score (RS) previously demonstrated that adjuvant chemotherapy plus endocrine therapy (CET) was associated with a significant survival benefit in women with node negative breast cancer (BC) and RS >31. However, the TAILORx trial, did not qua...

Descripción completa

Detalles Bibliográficos
Autores principales: Stabellini, Nickolas, Cao, Lifen, Towe, Christopher W., Amin, Amanda L., Montero, Alberto J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
RESEARCH ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10587951/
https://www.ncbi.nlm.nih.gov/pubmed/37766666
http://dx.doi.org/10.1002/cam4.6584

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10587951/
https://www.ncbi.nlm.nih.gov/pubmed/37766666
http://dx.doi.org/10.1002/cam4.6584

Ejemplares similares